Thu Dec 26 08:08:27 UTC 2024: ## Senores Pharmaceuticals IPO Overwhelmingly Subscribed, Listing Expected Monday

**MUMBAI, INDIA** – Senores Pharmaceuticals’ Initial Public Offering (IPO) concluded with a resounding success, exceeding expectations with a staggering 93.41 times oversubscription. The three-day bidding period (December 20-24) saw strong investor interest, raising a total of ₹582.11 crore (approximately $70 million USD). The IPO comprised a fresh issue of ₹500 crore and an offer-for-sale of up to 21,00,000 equity shares, priced between ₹372 and ₹391 per share.

All investor categories showed significant participation: Qualified Institutional Bidders (QIBs) subscribed 94.66 times, Non-Institutional Investors (NIIs) 96.11 times, retail investors 89.23 times, and employees 19.92 times.

The allotment of shares will be finalized on Thursday, December 26th, with investors receiving updates on fund debits or IPO mandate revocations by Friday, December 27th. The company’s shares are tentatively scheduled to list on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) on Monday, December 30th.

Despite market volatility, the grey market premium (GMP) for Senores Pharmaceuticals remains strong at ₹240, suggesting a potential listing gain of up to 60% for investors.

Senores Pharmaceuticals, incorporated in 2017, develops and manufactures pharmaceutical products for regulated markets in the US, Canada, and the UK, as well as emerging markets. As of September 30, 2024, the company had launched 55 products across key therapeutic areas.

Investors can check their allotment status on the BSE website ([https://www.bseindia.com/investors/appli_check.aspx](https://www.bseindia.com/investors/appli_check.aspx)) or the Link Intime India portal ([https://linkintime.co.in/MIPO/Ipoallotment.html](https://linkintime.co.in/MIPO/Ipoallotment.html)). Equirus Capital, Ambit, and Nuvama Wealth Management served as book-running lead managers, while Link Intime India acted as the registrar.

Read More